Needham Cuts Progenics (PGNX) to Hold Midday
PGNX Hot Sheet
Rating Summary:2 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 11 | New: 38
An analyst at Needham has just put out a midday downgrade on shares of Progenics Pharma (Nasdaq: PGNX). The firm moved its investment rating on the stock from Buy to Hold.
You May Also Be Interested In
- UPDATE: UBS Downgrades Avon Products (AVP) to Sell; Still Cautious Even After Sell Off
- Nomura Securities Raises PT and Estimates on PetSmart (PETM) After Good Q1
- Barclays Cuts PT and Estimates on Dell (DELL); Apple's (AAPL) Momentum Proves Disrupting
Create E-mail Alert Related Categories
DowngradesRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
